Journal Publications
Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.
Author(s) |
Date | Article Title | Journal |
|---|---|---|---|
|
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, Greg Curt, Mace Rothenberg, Ronit Simantov, Martin Murphy, Joseph Morrell, Joel Beetsch, Daniel J. Sargent, Howard I. Scher, Peter Lebowitz,, Richard Simon, Wilfred D. Stein, Susan E. Bates, Tito Fojo |
January 2017 | Estimation of Tumour Regression and Growth Rates During Treatment in Patients with Advanced Prostate Cancer: A Retrospective Analysis | The Lancet Oncology |
|
Kaitlyn Johnson, Axel Gomez, Jackson Burton, Douglas White, Arijit Chakravarty, Annette Schmid, Dean Bottino |
November 2018 | Directional Inconsistency Between Response Evaluation Criteria in Solid Tumors (RECIST) Time to Progression and Response Speed and Depth | European Journal of Cancer |
|
Omar Abdel-Rahman |
December 2018 | Statin Treatment and Outcomes of Metastatic Pancreatic Cancer: A Pooled Analysis of Two Phase III Studies | Clinical and Translational Oncology |
|
Tao Wang, Rong Lu, Sunny Lai, Joan H. Schiller, Fang Liz Zhou, Bo Ci, Stacy Wang, Xiaohan Gao, Bo Yao, David E. Gerber, David H. Johnson, Guanghua Xiao, Yang Xie |
February 2019 | Development and Validation of a Nomogram Prognostic Model for Patients with Advanced Non-Small-Cell Lung Cancer | Cancer Informatics |
|
Aakanksha Khandelwal, Mace Rothenberg, Sean Khozin, Amanda C Guidon, Michael Dougan, Leyre Zubiri, Laura Petrillo, Meghan E Sise, Alexandra-Chloe Villani, Douglas B Johnson, Osama Rahma and Elad Sharon |
July 2021 | Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data | Journal for ImmunoTherapy of Cancer |
|
Ahmad Y. Abuhelwa, Sarah Badaoui, Hoi-Yee Yuen, Ross A. McKinnon, Warit Ruanglertboon, Kiran Shankaran, Anniepreet Tuteja, Michael J. Sorich & Ashley M. Hopkins |
February 2022 | A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma | Cancer Chemotherapy and Pharmacology |
|
Alberto Martini, Anish B. Parikh, John P. Sfakianos, Francesco Montorsi, Matthew D. Galsky, William K. Oh, Che-Kai Tsao |
February 2021 | Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data | Prostate Cancer and Prostatic Diseases |
|
Alberto Martini, John Pfail, Francesco Montorsi, Matthew D. Galsky, William K. Oh |
April 2020 | Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial | Prostate Cancer and Prostatic Diseases |
|
Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James Hillis, Teilo H Schaller, Anthony A Amato, Allison Betof Warner, Priscilla K Brastianos, Tracey A Cho, Stacey L Clardy, Justine V Cohen, Jorg Dietrich, Michael Dougan, Christopher T Doughty, Divyanshu Dubey, Jeffrey M Gelfand, Jeffrey T Guptill, Douglas B Johnson, Vern C Juel, Robert Kadish, Noah Kolb, Nicole R LeBoeuf, Jenny Linnoila, Andrew L Mammen, Maria Martinez-Lage, Meghan J Mooradian, Jarushka Naidoo, Tomas G Neilan, David A Reardon, Krista M Rubin, Bianca D Santomasso, Ryan J Sullivan, Nancy Wang, Karin Woodman, Leyre Zubiri, William C Louv, Kerry L Reynolds |
July 2021 | Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors | Journal for ImmunoTherapy of Cancer |
|
Angela K. Green, Katherine E. Reeder-Hayes, Robert W. Corty, Ethan Basch, Mathew I. Milowsky, Stacie B. Dusetzina, Antonia V. Bennett, William A. Wood |
May 2017 | The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data | The Oncologist |
|
Anish B. Parikh, Alberto Martini, John Sfakianos, Matt D. Galsky, William K. Oh, Che-Kai Tsao |
February 2020 | Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data | Journal of Clinical Oncology |
|
Anne A. Eaton, Emily C. Zabor |
December 2021 | Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules | Statistics in Medicine |
|
Anway Giryes, Hani Oweira, Meinrad Mannhart, and Omar Abdel-Rahman |
July 2018 | Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials | Expert Review of Gastroenterology and Hepatology |
|
Aurélie Lombard, Hitesh Mistry, Leon Aarons, Kayode Ogungbenro |
October 2020 | Dose individualisation in oncology using chemotherapy‐induced neutropenia: Example of docetaxel in non‐small cell lung cancer patients | British Journal of Clinical Pharmacology |
